AI assistant
AbbVie Inc. — Director's Dealing 2024
Feb 20, 2024
29755_dirs_2024-02-20_bd53f689-0d00-4683-9062-1db77b1d5ad8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2024-02-15
Reporting Person: Reents Scott T (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-15 | Common Stock, $0.01 par value | A | 11800 | — | Acquired | 12609 | Direct |
| 2024-02-15 | Common Stock, $0.01 par value | A | 3146 | — | Acquired | 15755 | Direct |
| 2024-02-15 | Common Stock, $0.01 par value | A | 2398 | — | Acquired | 18153 | Direct |
| 2024-02-15 | Common Stock, $0.01 par value | A | 8912 | — | Acquired | 27065 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-15 | Option (Right to buy) | $0 | A | 31520 | Acquired | 2034-02-14 | Common Stock (31520) | Direct |
Footnotes
F1: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
F2: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
F3: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
F4: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
F5: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,507 on February 15, 2025, 10,507 on February 15, 2026, and 10,506 on February 15, 2027.